Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer

Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer ORIGINAL ARTICLE Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer Akito Hata, MD,* Hiroshige Yoshioka, MD,† Shiro Fujita, MD, PhD,* Kei Kunimasa, MD,† Reiko Kaji, MD,* Yukihiro Imai, MD, PhD,‡ Keisuke Tomii, MD,§ Masahiro Iwasaku, MD,† Akihiro Nishiyama, MD,† Tadashi Ishida, MD, PhD,† and Nobuyuki Katakami, MD, PhD* he presence of a mutation in the epidermal growth factor Introduction: Mutation of the epidermal growth factor receptor Treceptor (EGFR) gene is known to predict the efficacy of (EGFR) gene can predict the efficacy of EGFR-tyrosine kinase 1,2 EGFR-tyrosine kinase inhibitors (TKIs). Furthermore, the inhibitors. Different mutations have been shown to co-occur in a localization of EGFR mutations has been demonstrated to single tumor. However, the frequency of these so-called “complex affect response to EGFR-TKIs. Among EGFR gene muta- mutations” and the efficacy of gefitinib in treating patients with tions, an in-frame deletional mutation in exon 19 (Del-19) is these mutations are unclear. one of the strongest predictors of efficacy. The L858R point Methods: We investigated the frequency of complex mutations in mutation in exon 21 is also thought to be a good predictive 783 patients with non-small cell lung cancer seen at our institutes http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer

Katakami, Nobuyuki
Journal of Thoracic Oncology , Volume 5 (10) – Oct 1, 2010
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/complex-mutations-in-the-epidermal-growth-factor-receptor-gene-in-non-qQUne3BX0I

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181e8b3c5
pmid
20808254
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer Akito Hata, MD,* Hiroshige Yoshioka, MD,† Shiro Fujita, MD, PhD,* Kei Kunimasa, MD,† Reiko Kaji, MD,* Yukihiro Imai, MD, PhD,‡ Keisuke Tomii, MD,§ Masahiro Iwasaku, MD,† Akihiro Nishiyama, MD,† Tadashi Ishida, MD, PhD,† and Nobuyuki Katakami, MD, PhD* he presence of a mutation in the epidermal growth factor Introduction: Mutation of the epidermal growth factor receptor Treceptor (EGFR) gene is known to predict the efficacy of (EGFR) gene can predict the efficacy of EGFR-tyrosine kinase 1,2 EGFR-tyrosine kinase inhibitors (TKIs). Furthermore, the inhibitors. Different mutations have been shown to co-occur in a localization of EGFR mutations has been demonstrated to single tumor. However, the frequency of these so-called “complex affect response to EGFR-TKIs. Among EGFR gene muta- mutations” and the efficacy of gefitinib in treating patients with tions, an in-frame deletional mutation in exon 19 (Del-19) is these mutations are unclear. one of the strongest predictors of efficacy. The L858R point Methods: We investigated the frequency of complex mutations in mutation in exon 21 is also thought to be a good predictive 783 patients with non-small cell lung cancer seen at our institutes

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Oct 1, 2010

References

  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Lynch
  • EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    Paez
  • Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    Jackman
  • Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
    Costa
  • Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer
    Hsieh
  • Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern
    Wu
  • EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification
    Yokoyama
  • Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients
    Zhang
  • Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp
    Nagai
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Mitsudomi
  • First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group
    Kobayashi
  • Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons 19 and 21 in Japanese non-small cell lung cancer patients
    Masago
  • Detection of mutations in EGFR in circulating lung-cancer cells
    Maheswaran
  • Tissue heterogeneity of EGFR mutation in lung adenocarcinoma
    Sakurada
  • Assessing EGFR mutations
    Marchetti
  • Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer
    Chou
  • Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
    Balak
  • Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations
    Costa
  • Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma
    Bean
  • BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
    Costa
  • Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
    Mitsudomi
  • Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression
    Jiang
  • EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Kobayashi
  • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    Pao
  • EGFR mutation and response of lung cancer to gefitinib
    Toyooka